Key Quantitative Figures - Standalone (₹ in Lakhs)

Income Statement Q1 FY27:

  • Revenue from operations: ₹917.89
  • Other income: ₹19.60
  • Total income: ₹937.49
  • Cost of material consumed: ₹712.83
  • Employee benefits expense: ₹25.68
  • Finance costs: ₹0.59
  • Depreciation & amortization: ₹1.14
  • Other expenses: ₹60.98
  • Total expenses: ₹801.30
  • Profit before tax: ₹136.19
  • Current tax: ₹37.90
  • Deferred tax: ₹0.00
  • Profit for the period: ₹98.29
  • Total comprehensive income: ₹98.29

Comparative Performance:

  • Q1 FY27 revenue increased 82.5% YoY from ₹503.09 lakhs in Q1 FY26
  • Q1 FY27 profit increased 182.4% YoY from ₹34.80 lakhs in Q1 FY26
  • Basic EPS: ₹3.28 (Q1 FY27) vs ₹1.16 (Q1 FY26)

Capital Structure:

  • Paid-up equity share capital: ₹300.00 lakhs (face value ₹10 each)

Key Quantitative Figures - Consolidated (₹ in Lakhs)

Income Statement Q1 FY27:

  • Revenue from operations: ₹925.69
  • Other income: ₹19.60
  • Total income: ₹945.29
  • Cost of material consumed: ₹718.85
  • Employee benefits expense: ₹28.42
  • Finance costs: ₹0.59
  • Depreciation & amortization: ₹1.14
  • Other expenses: ₹64.15
  • Total expenses: ₹813.23
  • Profit before tax: ₹132.06
  • Current tax: ₹37.90
  • Deferred tax: ₹0.00
  • Profit for the period: ₹94.16
  • Total comprehensive income: ₹94.16
  • Basic EPS: ₹3.14

Subsidiary Performance:

  • Includes results of Oleo Biosciences Private Limited (CIN: U20110KA2026PTC218609)
  • Subsidiary contributed revenues of ₹7.80 lakhs
  • Subsidiary reported net loss after tax of ₹4.13 lakhs

Dates and Timeline

  • Board meeting date: August 12, 2026
  • Meeting time: 4:30 PM to 4:45 PM
  • Quarter ended: June 30, 2026
  • Results approval date: August 12, 2026
  • Limited review report date: August 12, 2026

Parties Involved

  • Subsidiary: Oleo Biosciences Private Limited
  • Statutory Auditors: Samir M. Shah & Associates (Firm Reg. No.: 122377W)
  • Stock Exchange: BSE Limited (Scrip Code: 526269)
  • Key personnel: Nitin S. Shah (Company Secretary, Compliance Officer & CFO), Nirmit D. Patel (Executive Director, DIN: 10239263)

Segment Information

  • The company operates in one segment: Nutrition-Chemical Industries

Accounting Policies and Notes

  • Figures regrouped and reclassified for comparability
  • Gratuity liability provided based on year-end actuarial valuation
  • Q4 FY26 figures are balancing figures between audited annual and reviewed YTD figures
  • Financial results reviewed by audit committee and board of directors

Auditor's Conclusion

Samir M. Shah & Associates conducted limited review and concluded that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement or fail to disclose required information under SEBI Listing Regulations.